Aerami Presents AER-901 Lung Deposition Modeling At ATS 2024
20 May 2024 //
GLOBENEWSWIRE
Aerami AER-901 Lung Data At ATS 2024
08 May 2024 //
GLOBENEWSWIRE
Aerami to Present Data Supporting AER-901 Dosing Regimen at CHEST 2023
05 Oct 2023 //
GLOBENEWSWIRE
Aerami Announces Presentation of Phase 1 Trial Data for Lead Program AER-901
12 Sep 2023 //
GLOBENEWSWIRE
Aerami Therapeutics Expands Management Team
02 Jun 2023 //
CONTRACT PHARMA
Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO
01 Jun 2023 //
GLOBENEWSWIRE
Aerami Announces Pharmacokinetic Data Demonstrating the Potential of AER-901
24 May 2023 //
GLOBENEWSWIRE
Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901
11 May 2023 //
GLOBENEWSWIRE
Aerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa
05 May 2023 //
GLOBENEWSWIRE
Aerami Therapeutics CEO Lisa Yañez passes away, lead heart disease biotech
05 May 2023 //
ENDPTS
Aerami to Investor Day with Leading Experts in Pulmonary Hypertension
03 Apr 2023 //
GLOBENEWSWIRE
Aerami Therapeutics Announces Expansion of the AER-901 Development Program
23 Feb 2023 //
GLOBENEWSWIRE
Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer
21 Dec 2022 //
GLOBENEWSWIRE
Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901
21 Dec 2022 //
GLOBENEWSWIRE
Aerami Therapeutics Appoints Lisa Yañez as Chief Operating Officer
16 Jun 2022 //
GLOBENEWSWIRE
Aerami & FoxWayne Enterprises Acquisition Mutually Agree to Terminate Agreement
04 Mar 2022 //
PRNEWSWIRE
Aerami to Merge with FoxWayne Enterprises to Become Public Company
07 Dec 2021 //
PRNEWSWIRE
Aerami Therapeutics Appoints Darlene Deptula-Hicks to its Board of Directors
11 Nov 2021 //
GLOBENEWSWIRE
Aerami Therapeutics Grabs ODD for Imatinib for Pulmonary Arterial Hypertension
25 Aug 2021 //
GLOBENEWSWIRE
Aerami Therapeutics Initiates Dosing in Phase 1 Trial of AER-901
24 Jun 2021 //
GLOBENEWSWIRE